Literature DB >> 4089527

Drug-induced agranulocytosis: evidence for the commitment of bone marrow haematopoiesis.

W Heit, H Heimpel, A Fischer, N Frickhofen.   

Abstract

Clinical and haematological features of 61 patients with drug-induced agranulocytosis (63 episodes) are presented. Multiple drug consumption was a common observation and complicated the attempt to incriminate a particular drug as being aetiologically involved. Bone marrow analysis shortly after the diagnosis revealed evidence for an impairment of proliferative granulopoiesis in the majority of cases. This observation was confirmed by in vitro culturing of granuloid precursor cells (CFU-c). Moreover, the data clearly demonstrated that drug-induced agranulocytosis may not be restricted to the granulocytic series. Thrombocytosis and reticulocytosis during the recovery phase are taken as an indication for the commitment of all haemopoietic cell lineages in agranulocytosis. These observations were in accordance with cytomorphological studies and in vitro culture data of erythroid precursor cells (CFU-e, BFU-e) of bone marrow aspirates taken in the initial phase of agranulocytosis. More than 25% of the patients showed a marked erythroid depression in the marrow.

Entities:  

Mesh:

Year:  1985        PMID: 4089527     DOI: 10.1111/j.1600-0609.1985.tb02813.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  9 in total

Review 1.  Drug-induced agranulocytosis.

Authors:  H Heimpel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

2.  Transient pancytopenia. A report from the International Agranulocytosis and Aplastic Study.

Authors:  M Keisu; W Heit; G Lambertenghi-Deliliers; J Parcells-Kelly; A Polliack; H Heimpel
Journal:  Blut       Date:  1990-10

3.  Relevance of in vitro studies of drug-induced agranulocytosis. Report of 14 cases.

Authors:  D M Parent-Massin; L Sensébé; M C Léglise; G Guern; C Berthou; C Riché; J F Abgrall
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

4.  The growth capacity of hematopoietic progenitor cells in severe neutropenia induced by famotidine.

Authors:  T Liersch; J H Beyer; G Krieger; K Vehmeyer
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

Review 5.  [Drug-induced bone marrow changes].

Authors:  Hans H Kreipe
Journal:  Pathologie (Heidelb)       Date:  2022-06-09

6.  Treatment of drug-induced agranulocytosis with recombinant granulocyte colony-stimulating factor (rh G-CSF).

Authors:  A Willfort; C Lorber; S Kapiotis; S Sertl; R Hainz; P Kirchweger; U Jäger; P A Kyrle; K Lechner; K Geissler
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

7.  Risks of rhG-CSF treatment in drug-induced agranulocytosis.

Authors:  H Demuynck; P Zachée; G E Verhoef; M Schetz; G Van den Berghe; P Lauwers; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

8.  Febuxostat-induced agranulocytosis in an end-stage renal disease patient: A case report.

Authors:  Xue Er Poh; Chien-Te Lee; Sung-Nan Pei
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

Review 9.  Idiosyncratic Drug-Induced Neutropenia and Agranulocytosis in Elderly Patients.

Authors:  Noel Lorenzo-Villalba; Maria Belen Alonso-Ortiz; Yasmine Maouche; Abrar-Ahmad Zulfiqar; Emmanuel Andrès
Journal:  J Clin Med       Date:  2020-06-10       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.